Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. Academic Article uri icon

Overview

abstract

  • The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory and effector CD8(+) T lymphocytes that efficiently prevent tumor development. However, the therapeutic effect of such a vaccine is limited. We also demonstrate that blockade of Cytotoxic T Lymphocyte Antigen 4 (CTLA-4) during vaccination enhances the frequency of NY-ESO-1-specific effector CD8(+) T cells producing IFN-γ and promotes lymphocyte migration to the tumor infiltrate. As a result, therapy with CL-14-NY-ESO-1 together with anti-CTLA-4 is highly effective in controlling the development of an established melanoma.

publication date

  • November 18, 2014

Research

keywords

  • Antigens, Neoplasm
  • CD8-Positive T-Lymphocytes
  • CTLA-4 Antigen
  • Cancer Vaccines
  • Immunotherapy
  • Melanoma, Experimental
  • Membrane Proteins

Identity

Scopus Document Identifier

  • 84925537115

Digital Object Identifier (DOI)

  • 10.1007/s00262-014-1634-8

PubMed ID

  • 25403749

Additional Document Info

volume

  • 64

issue

  • 3